Patty Wang

Acting General Manager
Medical and Pharmaceutical Industry Technology and Development Center

​​

Over 20 years of experiences in pharmaceutical industry, covering the scope of global business collaboration, industrial transformation, regulatory affairs and strategies for pharmaceutical development, Patty initiates and manages the interactions with government agencies such as Taiwan FDA, or Industrial Development Administration, Ministry of Economic Affairs (IDA, MOEA), being deeply engaged into industrial talents cultivation and sharing extensive experiences in providing GMP consultation in order to assist local pharma industry to comply with global standard.
As the current Acting General Manager of PITDC, Patty does not only pay attention to industrial development, but also to advance PITDC’s research capacities such as hot-melt extrusion skills etc. Through close communication and visits to participate in key activities and events in the various projects, Patty shares different perspectives across the pharmaceutical related issues. By her scientific background in Physical Chemistry- Quantum Mechanics expertise, and with management leadership, she successfully leads PITDC team to complete the government projects, including the IDA project of " Enhancing International Competitiveness in the Innovative Pharmaceutical Industry”, TFDA projects of "Enhanced Post-Market Drug Quality Monitoring and Notification Evaluation Management or Essential Drug Product or "Capacity Enhancement of Taiwan's Essential Drugs Manufacturing” etc.
 

Speech title & Synopsis

Taiwan-Malaysia: Opportunities for Pharmaceutical Industry Linkage and Business Collaboration

Starting from 2016, the Taiwan government introduced the New Southbound Policy to enhance Taiwan's relations with neighboring ASEAN countries. Over the past two decades, ASEAN's demographic structure had shifted towards an ageing population, with the proportion of the elderly individuals increasing from 5.3% in 2000 to 7.5% in 2022. This data implies the concerns about whether or not the healthcare system can cope with the foreseeable challenges on ageing population with a huge potential market for unmet medical needs. In Taiwan, most of the pharmaceutical manufacturers are specialized in generic drugs that we believe we can help.
In fact, Taiwan's top 10 exporting countries/regions of Western pharmaceutical preparations from 2021 to 2022 (excluding traditional Chinese medicine products), Southeast Asian countries account for 3 seats, namely Vietnam (5.24%), Thailand (3.30%), and Malaysia (3.02%).

Among the exporters of Western pharmaceutical products, Thailand, one of the three ASEAN seats, is in economic recession, Vietnam has grown 2.33%, and Malaysia has a significant growth of 67.95% compared with 2021 (1.8%). Therefore, we see the successful and potential business collaborations between Taiwan and Malaysia, and also the transparency of Malaysia’s pharmaceutical regulations gives comprehensive concept of registration requirements, which is informative for Taiwan pharmaceutical manufacturers. Therefore, Malaysia has become the potential market that pharmaceutical manufacturers have actively entered in recent years.